Anti-IP6K1 Polyclonal Antibody for WB, IHC-P, ELISA - Q92551

Core Product Specifications and Parameters

Biological Background: IP6K1 Function and Localization

• IP6K1 (Inositol hexakisphosphate kinase 1), also known as IHPK1 or PiUS, is a member of the inositol phosphate kinase family.
• It catalyzes the conversion of inositol hexakisphosphate (InsP6) to diphosphoinositol pentakisphosphate (InsP7/PP-InsP5) and inositol 1,3,4,5,6-pentakisphosphate (InsP5) to PP-InsP4.
• IP6K1 plays a key role in inositol phosphate metabolism and signaling, generating high-energy pyrophosphate-containing inositol phosphates.
• The protein localizes to both the cytoplasm and the nucleus.
• IP6K1 is regulated by phosphorylation and contains an ATP-binding domain, exhibiting kinase and transferase activities.
• Alternative splicing of the IP6K1 gene generates multiple isoforms.
• The human IP6K1 protein has a predicted molecular weight of approximately 50 kDa (50236 Da) and shares broad cross-species reactivity.

Experimental Guidance and Technical Tips

• The immunogen covers amino acids 1–220 of human IP6K1, targeting the N-terminal region; consider the potential detection of multiple isoforms if epitopes are conserved.
• For Western blot, use standard protocols and validate with appropriate positive and negative controls; the predicted band size is ~50 kDa.
• For immunohistochemistry (paraffin-embedded sections), optimize antigen retrieval and antibody titration for your specific tissue types.
• For ELISA, pair with a suitable detection antibody and confirm binding specificity using recombinant protein standards.
• As with any polyclonal antibody, lot-to-lot consistency should be verified, and cross-absorption steps may be considered to reduce background.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides a streamlined pipeline for sourcing high-quality IVD raw materials, including validated antibodies against targets like IP6K1 for inositol phosphate signaling research. We support diagnostic manufacturers and laboratories by offering bulk ancillary reagents and facilitating access to rare-target monoclonals and polyclonals, ensuring a reliable supply chain from concept to clinic.